<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857854</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F647-1702</org_study_id>
    <nct_id>NCT03857854</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Dermatomyositis Interstitial Lung Disease (Dm-ILD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of pirfenidone in subjects
      with dermatomyositis interstitial lung disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change from baseline (%) of FVC</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Dermatomyositis Interstitial Lung Disease (Dm-ILD)</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pirfenidone group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>treatment group</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>placebo group</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female or male subjects aged between 18 and 65 years of age

          2. According to the 1975 Borhan and Peter inflammatory myopathy diagnosed as
             dermatomyositis classification criteria (dermatomyositis, DM); or according to the
             revised clinical criteria for diagnosis of Sontheimer disease dermatomyositis (CADM).

          3. The diagnosis of pulmonary related Interstitial Lung Disease confirmed by HRCT

          4. Forced vital capacity (FVC) 40% to 80% predicted(include 40% and80% )

          5. Carbon monoxide diffusing capacity (DLco) 30% to 89% of predicted normal(include 30%
             and89% )

          6. Has received Glucocorticoid (hereinafter referred to as the &quot;hormone&quot;) and at least
             one immunosuppressive therapy for more than 3 months, the hormone dosage (prednisone
             equivalent dose calculation) should be less than 15mg/d for at least 1 months, should
             be immunosuppressant cyclophosphamide, mycophenolate mofetil, cyclosporine,
             tacrolimus, azathioprine and at least one of methotrexate in, and the type and dose of
             immunosuppressive agents should be at least stable more than 3 months. The hormone and
             immunosuppressant therapy scheme allows a reduction in the study period, but is not
             allowed to increase the volume.

          7. Women of childbearing age must agree and promise to use the form of medical care for
             at least 3 months after the trial, during the entire study period (including
             follow-up), and at the end of the trial.

          8. Patients volunteered to participate in the trial, with good compliance and ability to
             understand and sign informed consent before the study.

        Exclusion Criteria:

          1. Subjects not fulfill all of the above inclusion criteria

          2. Combined with other rheumatic diseases such as systemic sclerosis, systemic lupus
             erythematosus, Sjogren's syndrome, mixed connective tissue disease, undifferentiated
             connective tissue disease, and systemic vasculitis, such as ANCA associated
             vasculitis.

          3. Combined with other muscle diseases and may cause symptoms of myasthenia gravis
             disease, including neurological diseases (such as muscular dystrophy, myasthenia
             gravis, amyotrophic lateral sclerosis, Guillain Barre syndrome), cancer, drugs (such
             as statins), infection, genetic diseases, endocrine disorders, electrolyte disorder
             rhabdomyolysis.

          4. The clinical history, signs, serological examination, HRCT and bronchoalveolar lavage
             results suggest that in addition to inflammatory myopathy and other diseases caused by
             ILD, such as CTD, systemic vasculitis, infection, tumor, allergic pneumonia caused by
             sarcoidosis or environmental factors.

          5. Combined viscera function significantly abnormal patient:

               1. Liver:AST, ALT &gt;1.3ULN;Bilirubin &gt;1.5 ULN; Cirrhosis of the liver class for Child
                  Pugh C;

               2. Kidney:Creatinine clearance &lt;30 mL/min;

               3. Lung:Airway obstruction (pre-bronchodilator FEV1/FVC &lt;0.7);Other clinically
                  significant pulmonary abnormalities;

               4. Cardiovascular:i.Six weeks in severe hypertension, and out of control after
                  treatment(â‰¥160/100mmHg);ii.Myocardial infarction within six months;iii.A period
                  of 6 Months in unstable angina;iv.pulmonary artery hypertension and right heart
                  failure were significant;

               5. Gastrointestinal tract: with active peptic ulcer;

               6. Nervous system: Patients with psychiatric disorders;

               7. The blood coagulation function: History of thrombotic event within last
                  year(Including stroke and transient ischemic attack).

          6. Researchers, for other diseases (not inflammatory myopathy, such as malignant tumor)
             and make the life expectancy of &lt; 1 year of patients

          7. Allergic to test drugs or components (e.g. lactose)

          8. Patients with actinic dermatitis

          9. Previous treatment with nintedanib or pirfenidone

         10. Within 3 months to participate in other clinical trials;

         11. Combined medication: hormone &gt; 15mg/d, were less than 1 months before a stable dose of
             patients; the use of other immunosuppressive agents (except cyclophosphamide,
             mycophenolate mofetil, cyclosporine, tacrolimus, azathioprine, methotrexate and)
             patients; immunosuppression stable &lt; 3 months; during the study of hormones and
             immunosuppressive agents are likely to increase patients.

         12. Major surgery is planned during the treatment period.

         13. Pregnancy or lactation or make a schedule during the trials.

         14. Give the drug 28 days before or after administration of the 3 month period, women of
             childbearing age * are unwilling or unable to use contraceptive methods highly
             effective (according to ICH M3 (R2)), a highly effective means in the correct and
             consistent application of a barrier method when the failure rate of less than 1% per
             year. * women of childbearing age is defined has undergone menarche and in line with
             &quot;infertile women&quot; standard &quot;[female infertile women&quot; is defined as: postmenopausal
             period (12 months without menstruation, no other medical reasons) or permanent
             sterilization (e.g., tubal occlusion, hysterectomy, bilateral ovarian resection or
             bilateral tubal resection women)].

         15. According to the researchers,exhibited evidence of alcohol or drug abuse.

         16. Patients who were unable to understand or comply with the study procedures, including
             the completion of a self-administered questionnaire in the absence of help, were less
             likely to complete the trial.

         17. Severe limb weakness or joint disease that affects the stability and endurance of a
             patient who is unable to perform a 6 minute walking test.

         18. Clinical signs of malabsorption or needing parenteral nutrition.

         19. Patients who were unable to cope with pulmonary function tests.

         20. With mental illness .

         21. Researchers determined that they did not participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhang, Ling</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Zhang</last_name>
      <phone>+86-13501209210</phone>
      <email>rlzhang1006@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

